← Back to patent-cliff list
Nedisertib
Tier C — Watch / tradeNedisertib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DNA-PKcs
Indications (approved)：Pancreatic cancer, Biliary tract cancer, Gallbladder cancer, Solid tumour, Rectal cancer, Non-Hodgkin lymphoma, Synovial sarcoma, Leiomyosarcoma
Regional status
US
Phase II
2019-03-20
EU
Phase II
2019-03-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nedisertib?
Approved indications include: Pancreatic cancer, Biliary tract cancer, Gallbladder cancer, Solid tumour, Rectal cancer, Non-Hodgkin lymphoma, Synovial sarcoma, Leiomyosarcoma.
When does the Nedisertib patent expire?
No public expiry year is available for Nedisertib yet; this page updates once verified.
How do I get a quote for Nedisertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08